PBIO (PBIO)

Pembina Pipeline Corporation reported second-quarter 2026 adjusted EBITDA of CAD 1.064 billion, up 5% year-over-year, buoyed by strong operational performance and new assets entering service. Net earnings rose 23% to CAD 512 million, and adjusted earnings increased 10% to CAD 415 million.

Adjusted earnings climbed 10% to CAD 415 million. The Calgary-based midstream company said it remains on track to meet its 2026 outlook, reaffirming adjusted EBITDA guidance of CAD 4.35 billion to CAD 4.55 billion and saying it is trending toward the midpoint. The stock was unchanged at $24.99, ...

$PGY ($PGY) posted quarterly earnings results for Q2 2026 on Thursday, July 30th. The company reported earnings of $1.07 per share, beating estimates of $0.33 by $0.74. The company also reported revenue of $387,040,000, beating estimates of $359,584,603 by $27,455,397.You can see Quiver ...

The company missed first-quarter ... 9%. The earnings miss raised questions about spending discipline as BridgeBio prepares to launch three additional products—BBP-418 for a muscular dystrophy, encaleret, and infigratinib for skeletal disorders—over the next 12 months. Thursday’s results will test w…

BridgeBio Pharma stock has delivered a 149.6% return over the past three years, yet its valuation checks lean expensive and suggest the recent strength may already price in a lot of good news. With the company now highlighting a potential blockbuster opportunity around its encaleret program, ...